PMID- 20445057
OWN - NLM
STAT- MEDLINE
DCOM- 20100602
LR  - 20211020
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Print)
IS  - 0270-6474 (Linking)
VI  - 30
IP  - 18
DP  - 2010 May 5
TI  - Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's 
      disease.
PG  - 6315-22
LID - 10.1523/JNEUROSCI.5180-09.2010 [doi]
AB  - Alzheimer's disease (AD) is the most common age-related dementia. Unfortunately 
      due to a lack of validated biomarkers definitive diagnosis relies on the 
      histological demonstration of amyloid-beta (Abeta) plaques and tau 
      neurofibrillary tangles. Abeta processing is implicated in AD progression and 
      many therapeutic strategies target various aspects of this biology. While Abeta 
      deposition is the most prominent feature of AD, oligomeric forms of Abeta have 
      been implicated as the toxic species inducing the neuronal dysfunction. Currently 
      there are no methods allowing routine monitoring of levels of such species in 
      living populations. We have used surface enhanced laser desorption ionization 
      time of flight (SELDI-TOF) mass spectrometry incorporating antibody capture to 
      investigate whether the cellular membrane-containing fraction of blood provides a 
      new source of biomarkers. There are significant differences in the mass spectra 
      profiles of AD compared with HC subjects, with significantly higher levels of 
      Abeta monomer and dimer in the blood of AD subjects. Furthermore, levels of these 
      species correlated with clinical markers of AD including brain Abeta burden, 
      cognitive impairment and brain atrophy. These results indicate that fundamental 
      biochemical events relevant to AD can be monitored in blood, and that the species 
      detected may be useful clinical biomarkers for AD.
FAU - Villemagne, Victor L
AU  - Villemagne VL
AD  - Mental Health Research Institute, The University of Melbourne, Parkville, 
      Melbourne, Victoria 3052, Australia.
FAU - Perez, Keyla A
AU  - Perez KA
FAU - Pike, Kerryn E
AU  - Pike KE
FAU - Kok, W Mei
AU  - Kok WM
FAU - Rowe, Christopher C
AU  - Rowe CC
FAU - White, Anthony R
AU  - White AR
FAU - Bourgeat, Pierrick
AU  - Bourgeat P
FAU - Salvado, Olivier
AU  - Salvado O
FAU - Bedo, Justin
AU  - Bedo J
FAU - Hutton, Craig A
AU  - Hutton CA
FAU - Faux, Noel G
AU  - Faux NG
FAU - Masters, Colin L
AU  - Masters CL
FAU - Barnham, Kevin J
AU  - Barnham KJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/*blood/*diagnosis/diagnostic imaging
MH  - Amyloid beta-Peptides/*blood/metabolism
MH  - Biomarkers/*blood
MH  - Brain/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Protein Multimerization
MH  - Radionuclide Imaging
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
PMC - PMC6632738
EDAT- 2010/05/07 06:00
MHDA- 2010/06/03 06:00
PMCR- 2010/11/05
CRDT- 2010/05/07 06:00
PHST- 2010/05/07 06:00 [entrez]
PHST- 2010/05/07 06:00 [pubmed]
PHST- 2010/06/03 06:00 [medline]
PHST- 2010/11/05 00:00 [pmc-release]
AID - 30/18/6315 [pii]
AID - 3593000 [pii]
AID - 10.1523/JNEUROSCI.5180-09.2010 [doi]
PST - ppublish
SO  - J Neurosci. 2010 May 5;30(18):6315-22. doi: 10.1523/JNEUROSCI.5180-09.2010.